핵심 요약
- Moderna's new influenza vaccine has been approved
- The vaccine was designed for adults aged 50 and over
- It is the first influenza vaccine to use mRNA technology
숫자로 보기
506465
The American Food and Drug Administration approved Moderna's new influenza vaccine. This vaccine was designed for adults aged 50 and over and is the first influenza vaccine to use mRNA technology.
The approval of the vaccine followed two different paths. For adults between 50-64 years old, a traditional approval process was followed, while for those 65 years old and over, an accelerated approval process was used.
Moderna is required to validate the benefits of this vaccine in a later study.
반응 남기기
이 기사에 대해 질문
답변은 이 기사만을 바탕으로 AI가 생성합니다.
자주 묻는 질문
- What is Moderna's new influenza vaccine?
- Moderna's new influenza vaccine is the first influenza vaccine to use mRNA technology and was designed for adults aged 50 and over.
- How did the vaccine's approval process occur?
- The vaccine's approval process followed two different paths: a traditional approval process for adults between 50-64 years old, and an accelerated approval process for those 65 years old and over.
- What are the benefits of the vaccine?
- The benefits of the vaccine are required to be validated in a later study.